Accession Therapeutics Limited
Tania Selas has worked in various roles in the scientific industry since 2013. Tania began their career as a KTP associate at the University of Birmingham before moving on to work as an R&D Scientist and then a Senior Scientist at Cobra Biologics. In 2018, they joined Immunocore as a Senior Scientist and remained in this position until 2020. From there, they worked as a Senior Development Scientist at Evox Therapeutics Ltd until early 2022 when they began working as a Lead Scientist at Ipsen. Tania is currently employed as a Senior Scientist at Accession Therapeutics Limited, starting in June 2023.
Tania Selas completed their Bachelor of Science in Biology/Biological Sciences from Universidade de Vigo in 2011, with a one-year study at Aberystwyth University in 2009-2010. Tania then pursued a Master of Science in Molecular Biotechnology from the University of Birmingham in 2011-2012. Following this, they completed their Doctor of Philosophy in Chemical Engineering from the University of Birmingham in 2013-2017. In October 2018, they obtained a CMI Level 5 Diploma in Management and Leadership from the Chartered Management Institute.
Accession Therapeutics Limited
Accession Therapeutics’ elegant Trocept platform has potential to treat some of the most intractable and widespread forms of cancer. Based in Oxford, UK, it is developing a pipeline of products to the early clinical trial stage. Led by Bent Jakobsen, PhD FMedSci, a pioneer of T cell receptor therapy for cancer, the team is highly experienced intaking immuno-oncology products to the clinic. Accession Therapeutics’ Trocept technology is based on over a decade’s work and has generated exceptional preclinical data.Accession Therapeutics’ proprietary technology incorporates cancer-tropic viruses, the first time that viruses have been genetically modified to exclusively target cancer cells.As non-cancerous cells are not targeted by Trocept, systemic toxicity is eliminated meaning the drugs can be delivered intravenously and traffic to the tumour.Trocept’s highly potent and local activity gives it potential in some of the hardest to treat and most widespread forms of cancer. This includes breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.